The development of biomarkers based on quantitative imaging provides powerful non-invasive and cost effective diagnostic tools for stratified medicine. Capitalising on their multidisciplinary team of experts, Brainomix Limited, a start-up company from the University of Oxford, aims to become a leader in imaging biomarkers for neurological and cerebrovascular disorders.
From our roots in the University's software incubator, our vision is to equip physicians with automated medical imaging tools that will allow them to select the right patient for the right treatment.
The company's flagship product is the e-ASPECTS software. This automatically implements the Alberta Stroke Program Early CT Score (ASPECTS) clinical scoring methodology for detecting and assessing signs of stroke damage on computed tomography (CT) scans from patients with acute stroke. ASPECTS was invented by Professor Alastair Buchan, a co-founder of Brainomix and the Dean of Medicine and Professor of Stroke Medicine at the University of Oxford. The software will assist clinicians worldwide with the assessment of patient eligibility for life saving treatment. It will be used both by hospitals offering a stroke service and stroke clinical trials, providing major benefits to patients and the healthcare system.
The Brainomix co-founders and team consist of clinicians, scientists, technologists and business professionals specializing in neurology, neuroscience and medical imaging fields. Brainomix is ideally positioned to commercialise innovative medical imaging technologies that will revolutionise and improve the treatment of patients with neurological and cerebrovascular disorders.
From our roots in the University's software incubator, our vision is to equip physicians with automated medical imaging tools that will allow them to select the right patient for the right treatment.
The company's flagship product is the e-ASPECTS software. This automatically implements the Alberta Stroke Program Early CT Score (ASPECTS) clinical scoring methodology for detecting and assessing signs of stroke damage on computed tomography (CT) scans from patients with acute stroke. ASPECTS was invented by Professor Alastair Buchan, a co-founder of Brainomix and the Dean of Medicine and Professor of Stroke Medicine at the University of Oxford. The software will assist clinicians worldwide with the assessment of patient eligibility for life saving treatment. It will be used both by hospitals offering a stroke service and stroke clinical trials, providing major benefits to patients and the healthcare system.
The Brainomix co-founders and team consist of clinicians, scientists, technologists and business professionals specializing in neurology, neuroscience and medical imaging fields. Brainomix is ideally positioned to commercialise innovative medical imaging technologies that will revolutionise and improve the treatment of patients with neurological and cerebrovascular disorders.
Location: United Kingdom
Phone: +44 1865 582730
Total raised: $75.29M
Investors 1
| Date | Name | Website |
| - | Parkwalk A... | parkwalkad... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 24.02.2026 | Series C | $25.4M | - |
| 03.05.2025 | Series C | $18.57M | - |
| 23.12.2021 | Series B | $21.47M | - |
| 03.04.2018 | - | $9.85M | - |
Mentions in press and media 38
| Date | Title | Description |
| 13.03.2026 | Healthcare's Digital Lifeline: AI Battles Financial Strain and Revolutionizes Care | Healthcare confronts a severe financial crisis. Innovative AI, particularly agentic platforms, provides vital solutions. Translucent secured $27M to revolutionize hospital finance, offering real-time insights to combat margin leakage and pr... |
| 12.03.2026 | Brainomix Deploys 360 Stroke AI Imaging Platform Across WVU Health System | What You Should Know The Deployment: Brainomix has officially rolled out its AI imaging platform, Brainomix 360 Stroke, across all 25 sites of the West Virginia University (WVU) Health System. The Technology: The fully automated AI platform... |
| 11.03.2026 | HIMSS26 Wednesday Wrap-Up: Scaling Agentic AI, Securing the Enterprise, and Fixing Hospital Finance | Wednesday at HIMSS26 brought a necessary, pragmatic reality check to the AI fervor. As the initial hype of massive product launches settles, Day 3 conversations pivoted heavily toward the hard logistics of making these advanced systems actu... |
| 27.02.2026 | Brainomix Secures $25.4M to Accelerate U.S. AI Imaging Expansion | Brainomix, a leading AI medical imaging innovator, closed a $25.4 million Series C extension. This strategic investment boosts its U.S. market presence significantly. Funds will accelerate widespread deployment of its Brainomix 360 Stroke a... |
| 24.02.2026 | Power Protocol Receives $3M Investment From BITKRAFT Ventures | Power Protocol, a London, UK-based provider of a blockchain infrastructure platform for gaming and digital entertainment, received a $3M investment. BITKRAFT Ventures made the investment. The raise brought the total amount to $15.4M. The co... |
| 24.02.2026 | Brainomix: $25.4 Million Series C Extension Closed To Advance U.S. Expansion Of AI Imaging Platforms | Brainomix, an AI medical imaging company focused on stroke and lung fibrosis, announced a £4.8 million extension to its Series C financing, bringing the total raised in the round to £18.8 million, or approximately $25.4 million. The company... |
| 24.02.2026 | Brainomix Extends Series C Funding to $25.4M | Brainomix, an Oxford, UK-based company developing AI-powered imaging tools in stroke and lung fibrosis, raised $6.5M in Series Series C extension funding. The round was led by Parkwalk and Hostplus via the IP Group Hostplus Innovation Fund,... |
| 24.06.2025 | 3DR Labs and Brainomix Partner to Advance Stroke Care in the US Through Clinically Validated AI Imaging Solution | Our collaboration with Brainomix enhances the ability to quickly and accurately assess patient eligibility for interventions like thrombectomy based on stroke severity.” — Robert Falk, MD, Founder and Chief Medical Officer of 3DR LabsLOUISV... |
| 03.05.2025 | Brainomix completes £14m Series C funding round | We are pleased to announce our latest investment in Brainomix, a University of Oxford spinout pioneering AI-powered imaging tools in stroke and lung fibrosis, as part of a £14m Series C funding round. The funding will support commercial exp... |
| 28.03.2025 | 5 Interesting Startup Deals You May Have Missed In March: Robot Massages, Renting With Pets And Diagnosing Strokes | 3 Shares Email Facebook Twitter LinkedIn This is a monthly column that runs down five interesting startup funding deals every month that may have flown under the radar. Check out our February entry here. Spring has sprung and so have a list... |
Show more